Outcome of Pituitary Hormone Deficits After Surgical Treatment of Non-functioning Pituitary Macroadenomas (NFPMA)

Orsalia Alexopoulou (✉ orsalia.alexopoulou@uclouvain.be)
Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Endocrinology and Nutrition, Brussels. https://orcid.org/0000-0001-9933-7188

Valérie Everard
Cliniques Universitaires Saint-Luc, Department of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels.

Martine Etoa
Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Reference des Maladies Rares de l'Hypophyse, Le Kremlin-Bicêtre

Edward Fomekong
Cliniques Universitaires Saint-Luc, Department of Neurosurgery, Université Catholique de Louvain, Brussels.

Stéphane Gaillard
Hôpital Foch, Service de Neurochirurgie, Suresnes.

Fabrice Parker
Assistance Publique-Hôpitaux de Paris, Service de Neurochirurgie, Hôpital Bicêtre, Le Kremlin-Bicêtre.

Christian Raftopoulos
Cliniques Universitaires Saint-Luc, Department of Neurosurgery, Université Catholique de Louvain, Brussels.

Philippe Chanson
Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse. Univ. Paris-Saclay, Univ. Paris-Sud, Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique, Le Kremlin-Bicêtre.

Dominique Maiter
Cliniques Universitaires Saint-Luc, Department of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels.

Research Article

Keywords: Non-functionning pituitary macroadenomas (NFPMA), hypopituitarism, Hyperprolactinae-mia, NFPMA

DOI: https://doi.org/10.21203/rs.3.rs-163191/v1
Abstract

Objectives: Non-functioning pituitary macroadenomas (NFPMA) are benign tumors that cause symptoms of mass effects including hypopituitarism. Their primary treatment is trans-sphenoidal surgery. We aimed to determine the outcome of pituitary hormone deficits after surgical treatment of NFPMA and to identify factors predicting hormonal recovery.

Design: We retrospectively included 246 patients with NFPMA diagnosed and operated in one of the two participating centers. All hormonal axes were evaluated except growth hormone (GH). Postoperative improvement of pituitary endocrine function was considered if at least one hormonal deficit had recovered and a lower total number of deficits was observed one year after surgery.

Results: 80% (n=197) of patients had one or more pituitary deficits and 28% had complete anterior hypopituitarism. Besides GH, the gonadotropic and thyrotropic axes were the most commonly affected (68% and 62%, respectively). The number of hypopituitary patients dropped significantly to 61% at one year (p<0.001) and a significant improvement was observed for all hormonal axes, except central diabetes insipidus. Among patients with preoperative hypopituitarism, 88/175 (50%) showed improved pituitary function at one year. Both hyperprolactinemia at diagnosis and a lower tumor diameter independently predicted favourable endocrine outcome.

Conclusions: Hypopituitarism is present in 80% of patients with NFPMA and nearly half of them will benefit from sustained improvement after surgery. Hyperprolactinemia at diagnosis and lower tumor dimensions are associated with favourable endocrine prognosis. This supports the option of early surgery in NFPMA patients with pituitary deficits independent of the presence of visual disturbances.

Introduction

Non-functioning pituitary adenomas (NFPAs) are benign pituitary tumors that are typically associated with no clinical or biochemical signs of hormone excess (1,2,3). Thus, most of them are diagnosed as macroadenomas (NFPMA) when patients present symptoms of mass effects such as visual field defects, chronic headache and/or hypopituitarism (4). Occasionally they are discovered incidentally during a radiological examination performed for another indication (5,6). The prevalence of partial and complete hypopituitarism varies widely among studies, ranging from 37-85% and 6-29% of patients, respectively (7,8,9,10,11) and depending on patient selection criteria and criteria used for definition of pituitary deficiency.

Transsphenoidal surgery is the primary treatment of NFPMA (12,13). Even though tumor cannot be fully resected, surgery improves visual field defects in over 80% of patients and relieves headaches in the majority of them (14,15,16). Surgical resection can also reverse hypopituitarism and improvement of pituitary function has been reported in 16-48% of patients with macroadenomas (16,17). However, the number of studies specifically addressing the outcome of pituitary function after surgery of NFPMA only remains limited. They often used various diagnostic criteria for pituitary deficits, some included small numbers of patients and some provided conflicting results. Moreover, factors independently associated with
recovery of postoperative pituitary function have been infrequently evaluated in large series of patients (8,9,18,19).

The aims of the present study were: (i) to assess the prevalence of pituitary hormone deficits at diagnosis in a large series of patients undergoing surgery for a NFPMA, (ii) to evaluate post-operative evolution of pituitary functions, and (iii) to identify factors predicting hormonal recovery after primary surgical treatment.

**Patients And Methods**

*Patients*

This retrospective study included 246 patients with an initial diagnosis of NFPMA (diameter ≥ 10 mm on magnetic resonance imaging (MRI)) diagnosed and operated between 1988 and 2015 (median year of surgery: 2009) in one of the two participating centers (UCL Cliniques St Luc Brussels; n=144; Bicêtre Hospital Paris, n=102). A subset of these patients (n=106) was included in a previously published study on factors predicting postoperative relapse (20). We only included patients who had undergone primary pituitary surgery by the transsphenoidal route for NFPMA and with available endocrine evaluation both at baseline (n=246) and postoperatively, at 3 (n=244) and/or 12 months (n=219) after surgery. No patient had previously received tumor-directed medical treatment or radiotherapy and 27 patients presenting with acute symptomatic pituitary apoplexy were excluded from the study because of the known deleterious effects of this complication on pituitary functions. Follow-up was ended if the pituitary tumor required a further treatment within the first year after initial surgery.

Clinical characteristics and results of ophthalmological examination were recorded at diagnosis, whereas tumor characteristics at magnetic resonance imaging (MRI) were assessed preoperatively and after 3 and 12 months. Histological examination confirmed the diagnosis of pituitary adenoma in all patients. The study was approved by the Ethics Committee of the Cliniques universitaires Saint Luc (UCL) and no informed consent was requested as it was a retrospective study.

*Hormonal evaluation*

Four hormonal axes were considered in the evaluation of pituitary function. Thyrotropin (TSH) deficiency was defined as a free thyroxine (fT4) level below the normal range associated with low or normal TSH or, in 9 patients, as a fT4 in the lowest quartile of the normal range together with a more than 20%-reduction in fT4 compared to a previously recorded level, as proposed by the recent ETA guidelines for the diagnosis of central hypothyroidism (21). Patients were considered as corticotropin (ACTH)-deficient either if if they had a morning serum cortisol value below 138 nmol/L, which has been reported as the best cutoff value predicting ACTH insufficiency (22) or a suboptimal cortisol response to an insulin tolerance test (peak below 500 nmol/L). The diagnosis of gonadotropin deficiency was based on (i) a low morning serum testosterone (< 10 nmol/L) on at least two occasions with low or normal gonadotropins in men, (ii) amenorrhea with low serum estradiol and low/normal gonadotropins in premenopausal women, or (iii) gonadotropin concentrations below the normal age-related range in postmenopausal women. Diabetes insipidus (DI) was
defined as hypotonic polyuria > 4000 ml/day not reacting to fluid restriction but improving after desmopressin administration.

Prolactin concentrations were also recorded at diagnosis and during follow-up, while screening for growth hormone (GH) deficiency by provocative testing was not routinely performed preoperatively. Therefore, as the main goal of our study was to evaluate whether pituitary functions improved or worsened after surgery, we decided to not include the somatotropic axis in the evaluation of hormonal changes. Of note, a few patients could not be evaluated for a specific hormonal axis because of an interfering condition or treatment (L-T4 treatment for primary hypothyroidism in 3 patients; oral contraceptives in 4 women and glucocorticoid treatment in one man).

Postoperatively, the same criteria were applied to define hormone deficiencies while normal (or normalized) hormone concentrations without any hormonal replacement indicated a normal pituitary axis. Pituitary endocrine function was considered improved if at least one hormonal deficit had recovered in patients with preoperative hypopituitarism together with a total number of deficits lower than before surgery. In contrast, deterioration was defined as the occurrence of at least one new deficit with a total number of deficient axes greater than in the preoperative period.

**Radiological evaluation**

The size of the tumor was assessed by dedicated pituitary MRI. The largest tumoral surface was calculated on a selected coronal view, using the following equation: \( S = 3.1416 \times \frac{a \times b}{4} \) where \( a \) and \( b \) represent tumor width and height. Tumors were considered invasive if they extended laterally into the cavernous sinus region (23, 24) or inferiorly into the sphenoid sinus. Tumor progression was defined as an increase in size of a postoperative residue between 3 and 12 months, while recurrence was defined as reappearance of a tumor mass in a patient without residual tumor mass.

**Statistical Analysis**

Differences between subgroups were analyzed using unpaired Student’s t-tests for normally distributed continuous variables and Chi-Square (\( x^2 \)) tests for categorical variables. Multiple logistic regression analysis was performed to determine factors that independently predicted improvement of pituitary function at the 12 month time-point after surgery. The SPSS software (version 25; SPSS Inc., Chicago, IL) was used and \( P<0.05 \) was considered statistically significant.

**Results**

**Patient characteristics at diagnosis**

Table 1 shows the main characteristics of the total study group \((n=246)\) and of the two different center subgroups \((n=144\) and 102, respectively). The mean age \((\pm SD)\) was 55 ± 15 yr and the sex ratio showed a slight male predominance \((138\) men and 108 women, 52 being menopausal). The most prevalent presenting symptoms were visual disturbances \((65\%)\) and headache \((35\%).\) A clinical hypogonadism was detected in
28% of men and in 54% of pre-menopausal women, while galactorrhea was reported only by a minority of patients. Preoperative ophthalmologic evaluation showed a visual field deficit in 154/241 patients (64%) and a significant decrease in visual acuity (less than 0.5 at at least one eye) in 62/214 (29%) Pituitary tumors were discovered incidentally in 59 patients (24%). However, despite this incidental diagnosis, 49% of these patients had visual impairment, 20% complained from headaches and 78% had some degree of pituitary dysfunction.

Baseline endocrinological evaluation revealed hypopituitarism in 197/246 patients (80%), with more than half of all patients showing at least two pituitary deficits and 28% having complete anterior hypopituitarism. The gonadotropic and thyrotropic axes were the most commonly affected with 68% and 62% of evaluable patients showing biochemical evidence of central hypogonadism and hypothyroidism, respectively. Corticotropic insufficiency was noted in 32% of patients while diabetes insipidus was present in only two patients (0.8%) with a silent hemorrhagic tumour at the time of clinical presentation. Hyperprolactinaemia was observed in about one half of the patients, with maximal prolactin concentrations being 5.9-fold above the upper normal limit for age and gender. With the exception of headache, no significant difference was observed between the cohorts from the two participating centers (Table 1).

Pituitary tumor Imaging and post-surgical outcome

Overall, mean tumor height and width were close to 25 mm and 59% of patients had invasive tumors. NFPMAs had a slightly greater height in the Belgian subgroup but in contrast were larger and more invasive in the French cohort (possibly resulting from local differences in patient recruitment and surgical threshold). The tumoral surface was however similar between the two subgroups (Table 2). The presence of a postsurgical tumor remnant was observed in 64% of all patients, and was more frequent in the Bicêtre (72%) than in the Brussels cohort (59%), a difference attributable to a more frequent cavernous sinus invasion. Overall, 27 patients (13%) had tumor progression or recurrence after one year of follow-up.

When compared with the 49 patients without preoperative hypopituitarism, patients with at least one pituitary deficiency had larger and taller tumors, but there was no difference in invasiveness (Table 3). Interestingly enough, the difference was more significant for tumor width than height. Visual impairment and hyperprolactinaemia were also more frequent in pituitary-deficient patients, while age and sex ratio were not significantly different. There was also no significant difference between these two subgroups regarding the prevalence of a postoperative tumor residue or in the rate of tumor progression or recurrence at one year (data not shown).

Postoperative hormonal evaluation

At the first hormonal evaluation performed three months after surgery, the proportion of patients with at least one pituitary deficit had dropped from 80% to 69% (p< 0.001) and this percentage further decreased to 61% at 12 months (p< 0.001) (Figure 1A). In particular, the number of patients with two deficits or more was reduced from 55 to 38% at one year (p<0.001) and the mean number of affected pituitary axes was also significantly reduced from 1.63 at baseline to 1.26 at 12 months (p<0.001). Sustained improvement was observed for all investigated anterior pituitary hormonal axes, but was more pronounced for the
gonadotropic and thyrotropic than for the corticotropic axis (Figure 1B). In contrast, and as expected, central DI was more frequent both at three (11.6%) and 12 months (7.4%) compared to less than 1% preoperatively (p< 0.001). The presence of DI one year after surgery was positively associated with tumor size at the time of surgery (p< 0.01).

When considering only patients with preoperative hormonal deficiency and available follow-up at one year (n=175), improvement of pituitary endocrine function was observed in 87 subjects (50%), while worsening was seen in 25 (14%). Among the 44 patients who had normal pituitary function at baseline, only 10 had a new postoperative deficit (with the caveat that GH secretion was not analyzed in the present study). Altogether a deterioration of endocrine pituitary function was thus observed in only 35/219 patients (16%).

When comparing patients with and without hyperprolactinaemia (Table 4), more hyperprolactinemic patients had hypopituitarism at diagnosis and a greater number of these patients showed improvement or recovery of normal pituitary function 12 months postoperatively. However, these differences involved all anterior pituitary hormonal axes, and not specifically the gonadotropic axis. In other terms, hypogonadism was not particularly more prevalent in patients with hyperprolactinemia and did not recover more frequently in those who normalized their prolactin levels postoperatively (data not shown).

Predictive factors of hormonal outcome

To determine possible predictors of postoperative improvement of endocrine function, the following parameters were evaluated in the subgroup of patients with preoperative pituitary deficits: gender, age at diagnosis, visual impairment, hyperprolactinemia, tumor dimensions and tumor invasiveness. In univariate analysis, female gender (p<0.05), hyperprolactinemia at diagnosis (p<0.001) and lower tumor height and width (p<0.001) were associated with a global improvement of pituitary function (Table 5). However, in multivariate analysis the only parameters independently predicting favorable endocrine outcome were hyperprolactinaemia and either tumor height or width. Indeed, as these two parameters were closely associated (r=0.683; p<0.001), they had to be included in separate multivariate analyses. However, here also we observed that tumor width was a more powerful factor than tumor height to predict postoperative evolution of pituitary functions (Table 5).

Discussion

As they are not associated with clinically relevant hormonal hypersecretion, NFPMA remain most often undiagnosed until they present symptoms of tumor mass effect. (1). We confirm in our study that most of these tumors present with headaches and/or visual alterations. NFPMA may also be diagnosed incidentally in about one quarter of cases (1,4). However, autopsy series show that macroadenomas represent less than 1% of pituitary tumors discovered postmortem, thus suggesting that there may be some connection between the presence of an “incidental” macroadenoma and the symptoms leading to brain imaging. In our surgical series, NFPMA were diagnosed “incidentally” in 24% of patients, and even though pituitary incidentalomas by definition are not diagnosed on the basis of tumor-related symptoms, a significant proportion of these patients had headaches, visual deficit at examination and/or pituitary dysfunction that had remained so far undiagnosed.
Hypopituitarism is a common complication of NFPMA at diagnosis. About 60-80% of patients have at least one pituitary hormone deficiency prior to surgery and, depending on the studies, the somatotropic and gonadotropic deficits are the most frequently affected (3,4,11). The prevalence of central hypothyroidism may however be underestimated as the diagnosis of TSH insufficiency remains often difficult given the wide range of normal free thyroxine values in the general population, and the paucity of specific symptoms and signs (21,22). In fact, we found a quite similar prevalence of gonadotropin and TSH deficits in our patients with NFPMA (68% and 62%, respectively), while ACTH deficiency was much less frequent (32%) and diabetes insipidus was very uncommon. Like in many other centers, GH deficiency was not systematically assessed preoperatively. As changes in pituitary function are expected after surgery, preoperative GH testing seems useless as it would need to be repeated after surgery (6). Moreover, our regular practice is to perform GH stimulation testing only in patients who could further benefit from GH therapy. However, when it is done in a systematic way, the majority of patients will be found to be GH-deficient (25).

Preoperative hypopituitarism was associated with tumor size and invasiveness, hyperprolactinemia and the presence of visual disturbances as previously reported by different studies (17,18,26,27,28). Interestingly, we found that tumor width was more closely associated with endocrine dysfunction than tumor height. It is tempting to hypothesize that larger tumors will be more prone to compress the normal gland or the pituitary stalk while taller ones will more frequently induce visual complications, although both dimensions are usually correlated.

Preoperative hyperprolactinemia was observed in nearly half of our patients, as usually observed (28,29,30). It mainly results from pituitary stalk compression (28) and was still present postoperatively in only 16% of patients, indicating that surgery had a significant effect on relieving stalk effect. Previous studies as well as our own data have suggested that in patients with mildly elevated prolactin levels prior to surgery, pituitary function was more likely to recover (17,26,29). These observations suggest the presence of intact pituitary tissue and imply that the mechanism of hypopituitarism may be compression of the portal circulation rather than destruction of the normal pituitary gland (29). A functional inhibitory effect of hyperprolactinaemia on the gonadal function might also be evoked but our data indicate that this is not the main mechanism explaining hypopituitarism in patients with NFPMA.

According to recent guidelines on diagnosis and treatment of NFPMA, surgery is indicated in patients with enlarging tumors or symptomatic tumors with mass effects (1,5,12,13). Surgical management of NFPAs indeed provides successful symptom relief with acceptable morbidity and mortality (16,31). Overall, transsphenoidal surgery – whether microscopic or endoscopic – leads to complete adenoma resection in 20-40% of cases and allows significant debulking in most of them, with an overall complication rate of 5-9% (32,33,34). In contrast, few large studies have extensively evaluated the impact of surgery on pituitary hormonal functions in patients with NFPMA.

While early studies concluded that transsphenoidal surgery carried a significant risk of sacrificing remaining anterior pituitary function, especially in patients with large and compressing tumors (30,35), it is clear from more recent reports that postoperative pituitary function can now be better preserved and even be improved or normalized. We performed a review of several studies published on this issue over the last two decades
Large variations are observed between these studies, likely because of differences in patient recruitment and surgical indication, in the definition of pituitary deficits, as well as in surgeon’s experience and procedure. Overall, resolution of one or more hormonal deficits by surgery can be expected in 15-50% of patients, but obviously some studies reported a clear improvement in pituitary function (8,9,17,28,36,37) whereas others could not demonstrate such beneficial effect (15,19,38,39). In the present study, we observed that 50% of all patients with a preoperative hormone deficiency showed improvement of pituitary function after surgery, while a deterioration was seen in less than 20% of all operated patients (whether hormone-deficient or not). Therefore, although Endocrine Society guidelines indicate that hypopituitarism is only a relative surgical indication in patients with NFPA (12), our data suggest that transsphenoidal surgery should not only aim at resolution of visual deficits but also at preservation or improvement of pituitary functions in case of tumor progression (9,33). Furthermore, we also found that permanent DI, which is a common complication of pituitary surgery (5-10%), is more likely to occur when operating a large tumor, which also argues for early surgery.

We also tried to identify factors influencing the outcome of pituitary function after surgery. Few large studies have previously addressed this question (17,18,37). We found that hyperprolactinemia and a lower tumor diameter were significantly and independently associated with a higher chance of pituitary function recovery. Either tumor width or height predicted endocrine outcome, thus extending results from previous studies (8,18). More precisely in the study of Jahangiri et al, residual size of the normal pituitary gland rather than tumor volume predicted the ability of pituitary axes to improve after transsphenoidal surgery. We did not evaluate this parameter in our study but it is likely that residual normal gland and tumor size (in particular tumor width) are inversely correlated and that endocrine normalization should reflect the amount of functional pituitary tissue which is relieved by decompression. We did not find, however, an association between age and post-operative endocrine outcome, in contrast with a previous report showing that younger age predicted better hormonal recovery (18).

The main limitations of our study are inherent to its retrospective nature. There were some missing data and each hormone outcome was analyzed in a different (though large) sample size. We also did not perform preoperative testing of GH secretion, which could have led to an underestimation of the degree of pituitary dysfunction. However, isolated GH deficiency is rather rare. On the other hand, our cohort of patients with a confirmed and operated NFPMA was quite large, patients were managed with similar protocols in both centers, surgeries were performed by a limited number of experienced neurosurgeons, and follow-up data at one year were available for 88% of the patients.

In conclusion, in this large cohort of patients operated for a NFPMA, we show that hypopituitarism is present in 80% of the patients before surgery and that, besides GH, the gonadotropin and TSH axes are the more frequently affected. Among patients with preoperative hypopituitarism, nearly half of them will benefit from sustained improvement of pituitary function. Hyperprolactinemia at diagnosis and a lower tumor diameter are independently associated with a favorable endocrine prognosis. As resolution of one or more hormonal deficits can be achieved in a significant number of patients, we suggest that early surgery by experienced pituitary neurosurgeons should be discussed in patients with a growing tumor and hypopituitarism, regardless of visual disturbances.
Declarations

Funding

This work has not received any funding

Conflicts of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Ethics approval

The study was approved by the Ethics Committee of the Cliniques Universitaires Saint Luc (UCL) and no informed consent was requested as it was a retrospective study.

Consent for publication

All authors approve the submission

Availability of data and material

Data and code for statistical analyses are available upon request.

References

1. Molitch ME (2017) Diagnosis and Treatment of Pituitary Adenomas. A Review. JAMA 317(5) 516-524. (doi: 10.1001/jama.2016.19699)
2. Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Practice & Research Clinical Endocrinology & Metabolism 23: 625-638. (doi:10.1016/j.beem.2009.05.005)
3. Jaffe CA (2006) Clinically non-functioning pituitary adenoma. Pituitary 9: 317-21. (doi: 10.1007/s11102-006-0412-9)
4. Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB, Wass JA, Karavitaki N (2016) Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. European Journal of Endocrinology 174: 137-145. (doi: 10.1530/EJE-15-0967).
5. Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S (2015) French Endocrinology Society non-functioning pituitary adenoma work-group. Management of clinically non-functioning pituitary adenoma. Annals of Endocrinology 76: 239-47. (doi: 10.1016/j.ando.2015.04.002) Epub 2015 Jun 10
6. Freda PU, Bruce JN, Khandji AG, Jin Z, Hickman RA, Frey E, Reyes-Vidal C, Otten M, Wardlaw SL, Post KD (2020) Presenting Features in 269 Patients With Clinically Non functioning Pituitary Adenomas Enrolled in a Prospective Study. Journal of the Endocrine Society 4: 1-13. ( doi: 10.1210/jendso/bvaa021.)
7. M R Drange 1, N R Fram, V Herman-Bonert, S Melmed (2000) Pituitary tumor registry: a novel clinical resource. Journal of Clinical Endocrinology and Metabolism 85: 168-74. (doi: 10.1210/jcem.85.1.6309)

8. Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, Wang C, Swerdloff RS, Kelly DF (2008) Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 63: 709-18. (doi: 10.1227/01.NEU.0000325725.77132.90)

9. Webb SM, Rigla M, Wägner A, Oliver B, Bartumeus F (1999) Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84: 3696-3700. (doi: 10.1210/jcem.84.10.6019)

10. Dekkers OM, Pereira AM, Romijn JA (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism 93: 3717-3726. (doi: 10.1210/jcem.2008-0643)

11. Raverot G, Assié G, Cotton F, Cogne M, Boulin A, Dherbomez M, Bonneville JF, Massart C (2015) Biological and radiological exploration and management of non-functioning pituitary adenoma. Annals of Endocrinology 76: 201-209. (doi: 10.1016/j.ando.2015.04.005).

12. Freda PU, Beckers AM, Katzenelson L, Molitch ME, Montori VM, Post KD, Vance ML (2011) Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 96: 894-904. (doi: 10.1210/jc.2010-1048)

13. Lucas JW, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G (2016) Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery 79: 533-535. (doi:227/NEU.0000000000001389)

14. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M (2007) Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60: 993-1002 (doi: 10.1227/01.NEU.0000255459.14764.BA.)

15. Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schröijen MA, Smit JW, Romijn JA (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism 91: 1796-801. (doi: 10.1210/jc.2005-2552)

16. Penn DL, Burke WT, Laws ER (2018) Management of non-functioning pituitary adenomas: surgery. Pituitary 21: 145-153. (doi: 10.1007/s11102-017-0854-2)

17. Nomikos P, Ladar C, Fahlbusch R, Buchfelder M (2004) Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas -- a study on 721 patients. Acta Neurochirurgica 146: 27-35. (doi: 10.1007/s00701-003-0174-3)

18. Jahangiri A, Wagner JR, Han SW, Tran MT, Miller LM, Chen R, Tom MW, Ostling LR, Kunwar S, Blevins L, Aghi MK (2016) Improved versus worsened endocrine function after transsphenoidal surgery for non-functional pituitary adenomas: rate, time course, and radiological analysis. Journal of Neurosurgery 124: 589-595. (doi: 10.3171/2015.1.JNS141543)

19. Kim JH, Lee JH, Lee JH, Hong AR, Kim YJ, Kim YH (2018) Endoscopic Transsphenoidal Surgery Outcomes in 331 Nonfunctioning Pituitary Adenoma Cases After a Single Surgeon Learning Curve. World Neurosurgery 109: 409-416. (doi: 10.1016/j.wneu.2017.09.194)
20. Sophie Brochier 1, Françoise Galland, Michèle Kujas, Fabrice Parker, Stephan Gaillard, Christian Raftopoulos, Jacques Young, Orsalia Alexopoulou, Dominique Maiter, Philippe Chanson (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology 163: 193-200. (doi: 10.1530/EJE-10-0255)

21. Persani L, Brabant G, Dattani M, Bonomi M, Feldt-Rasmussen U, Fliers E, Gruters A, Maiter D, Schoenmakers N, van Trotsenburg ASP (2018) 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. European Thyroid Journal 7: 225-237( doi: 10.1159/000491388)

22. Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule DG, Tordjman K (2008) Corticotropin tests for hypothalamic-pituitary-adrenal Insuciency: a metaanalysis, Journal of Clinical Endocrinology & Metabolism 93 4245–4253

23. E Knosp , E Steiner, K Kitz, C Matula (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical fi ndings. Neurosurgery 33: 610-7 (doi: 10.1227/00006123-199310000-00008)

24. Micko AS, Wöhrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verication and its correlation with an MRI-based classication. Journal of Neurosurgery 122: 803-11. ( doi: 3171/2014.12.JNS141083)

25. Molitch ME (2014) Nonfunctioning pituitary tumors. Handbook of Clinical Neurology 124: 167-84. (doi: 10.1016/B978-0-444-59602-4.00012-5)

26. Arafah BM (1986) Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.Journal of Clinical Endocrinology and Metabolism 62: 1173-1179. (doi: 10.1210/jcem-62-6-1173)

27. Losa M, Donofrio CA, Barzaghi R, Mortini P (2013) Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients' characteristics. European Journal of Endocrinology 169: 735-742. (doi: 10.1530/EJE-13-0515)

28. Zhang R, Wang Z, Gao L, Guo X, Feng C, Deng K, Lian W, Yao Y, Feng M, Bao X, Wang R, Xing B (2019) Clinical Characteristics and Postoperative Recovery of Hypopituitarism in Patients with Nonfunctional Pituitary Adenoma. World Neurosurgery 126:1183-1189. ( doi: 10.1016/j.wneu.2019.03.062)

29. Marazuela M, Astigarraga B, Vicente A, Estrada J, Cuerda C, García-Uría J, Lucas T (1994) Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas. Journal of Endocrinological Investigation 17: 703-707. (doi: 10.1007/BF03347763)

30. Comtois R, Beauregard H, Somma M, Serri O, Aris-Jilwan N, Hardy J (1991) The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68: 860-6. (doi: 10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4)

31. Alzhrani G, Sivakumar W, Park MS, Taussky P, Couldwell WT (2018) Delayed Complications After Transsphenoidal Surgery for Pituitary Adenomas. World Neurosurgery 109: 233-241.( doi:}
32. Mohammad Hassan Murad, M M Fernández-Balsells, Amelia Barwise, Juan F Gallegos-Orozco, Anu Paul, Melanie A Lane, Julianna F Lampropulos, Inés Natividad, Lilisbeth Perestelo-Pérez, Paula G Ponce de León-Lovatón, Felipe N Albuquerque, Jantey Carey, Patricia J Erwin, Victor M Montori (2010) Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clinical Endocrinology 73: 777-791. (doi: 10.1111/j.1365-2265.2010.03875.x. DOI: 10.1016/j.wneu.2017.09.192)

33. Halvorsen H, Ramm-Pettersen J, Josefsen R, Rønning P, Reinlie S, Meling T, Berg-Johnsen J, Bollerslev J, Helseth E (2014) Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochirurgica 156: 441-449. (doi: 10.1007/s00701-013-1959-7.)

34. Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15: 71-83. (doi: 10.1007/s11102-011-0347-7)

35. Nelson AT Jr, Tucker HS Jr, Becker DP (1984) Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas. Journal of Neurosurgery 61 577-580. (doi: 10.3171/jns.1984.61.3.0577)

36. Lampropoulos KI, Samonis G, Nomikos P (213) Factors influencing the outcome of microsurgical transsphenoidal surgery for pituitary adenomas: a study on 184 patients. Hormones 12: 254-264. (doi: 10.1016/j.wneu.2016.04.059)

37. Wats A, Easwaran A, McNeill P, Wang YY, Inder W, Caputo C (2017) Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: Results from a single Australian
### Tables

**TABLE 1.** Baseline characteristics at diagnosis in all patients with a non-functioning pituitary macroadenoma (n=255)

|                                | All patients (N=246) | St Luc (N=144) | Bicêtre (N=102) | P     |
|--------------------------------|----------------------|----------------|-----------------|-------|
| **Sex ratio (men/women)**      | 138/108              | 81/63          | 57/45           | NS    |
| **Age (years ; mean ± SD)**    | 56 ± 15              | 57 ± 15        | 54 ± 15         | NS    |
| **Visual disturbances**        | 159/245 (65%)        | 92/143 (64%)   | 67/102 (66%)    | NS    |
| **Headache**                   | 86/246 (35%)         | 60/144 (42%)   | 26/102 (26%)    | 0.01  |
| **Clinical hypogonadism:**     |                      |                |                 |       |
| Erectile dysfunction (men)      | 39/138 (28%)         | 24/81 (30%)    | 13/51 (26%)     | NS    |
| Menstrual cycle disorders      | 29/54 (54%)          | 12/28 (43%)    | 16/24 (67%)     | NS    |
| Galactorrhea                   | 17/245 (7%)          | 8/143 (6%)     | 9/102 (10%)     | NS    |
| Incidental finding             | 60/245 (24%)         | 35/143 (25%)   | 24/102 (24%)    |       |
| **Number of deficient hormonal axes** |                  |                |                 | NS    |
| None                           | 49 (20%)             | 34 (24%)       | 15 (15%)        |       |
| 1                              | 62 (25%)             | 32 (22%)       | 30 (29%)        |       |
| 2                              | 66 (27%)             | 36 (25%)       | 30 (29%)        |       |
| 3                              | 68 (28%)             | 41 (29%)       | 27 (27%)        |       |
| 4                              | 1 (0.4%)             | 1 (0.7%)       | 0 (0%)          |       |
| **Type of hormonal deficiency**|                      |                |                 | NS    |
| gonadotrope                    | 165/242 (68%)        | 95/140 (68%)   | 70/102 (69%)    |       |
| thyreotrope                    | 150/243 (62%)        | 84/141 (60%)   | 66/102 (65%)    |       |
| corticotrope                   | 79/245 (32%)         | 45/144 (31%)   | 34/101 (34%)    |       |
| diabetes insipidus             | 2/246 (0.8%)         | 1/144 (0.7%)   | 1/102 (1%)      |       |
| Hyperprolactinaemia (%)        | 119/246 (48%)        | 76/144 (53%)   | 43/102 (42%)    | NS    |
| PRL concentration (xULN)       | 2.2 (1.03-5.9)       | 2.3 (1.07-5.3) | 2.0 (1.03-5.9)  | NS    |
*Visual disturbances include both visual field defects and reduced visual acuity; ULN: upper limit of normal; §: Prolactin (PRL) concentrations are shown only for the subset of patients with hyperprolactinemia

**TABLE 2.** Pituitary tumor characteristics at diagnosis and outcome after surgery

|                          | All patients (N=246) | St Luc Brussels N=144 | Bicêtre Paris N=102 | P value |
|--------------------------|----------------------|------------------------|----------------------|---------|
| Tumor height (mm)        | 24.7 ± 9.2           | 25.7 ± 9.6             | 23.1 ± 8.3           | 0.042   |
| Tumor width (mm)         | 24.5 ± 8.1           | 23.2 ± 8.0             | 26.2 ± 7.8           | 0.01    |
| Tumor surface (mm²)      | 517 ± 390            | 516 ± 423              | 519 ± 342            | NS      |
| Invasive adenoma         | 144/243 (59%)        | 76/144 (53%)           | 67/99 (68%)          | 0.024   |

|                          | All patients (N=246) | St Luc Brussels N=144 | Bicêtre Paris N=102 | P value |
|--------------------------|----------------------|------------------------|----------------------|---------|
| Post-surgical tumor residue | 153/239 (64%)     | 83/142 (59%)           | 70/97 (72%)          | 0.03    |
| Progression or relapse at 1 year | 27/202 (13%) | 8/112 (7%)             | 19/90 (21%)          | 0.01    |

**TABLE 3.** Comparison between patients with and without pituitary deficiency at baseline

|                                  | Patients without pituitary deficit (n=49) | Patients with pituitary deficit(s) (n=197) | P value |
|----------------------------------|------------------------------------------|-------------------------------------------|---------|
| Sex ratio (men/women)            | 23/26                                    | 115/82                                    | NS      |
| Age (years; mean ± SD)           | 52 ± 16                                  | 56 ± 14                                   | NS      |
| Visual disturbances*             | 23/49 (47%)                              | 136/196 (69%)                             | 0.004   |
| Hyperprolactinaemia              | 17/49 (35%)                              | 102/197 (52%)                             | 0.032   |
| Tumor height (mm)                | 22.1 ± 8.1                               | 25.3 ± 9.4                                | 0.032   |
| Tumor width (mm)                 | 20.9 ± 7.3                               | 25.4 ± 8.0                                | 0.001   |
| Invasive adenoma                 | 28/49 (57%)                              | 115/194 (59%)                             | NS      |

*Visual disturbances include both visual field defects and reduced visual acuity

**TABLE 4.** Comparison of pre- and post-surgical pituitary function in patients with and without hyperprolactinaemia at diagnosis
|                          | Patients without hyperprolactinaemia (n=127) | Patients with hyperprolactinaemia (n=119) | P   |
|--------------------------|---------------------------------------------|-------------------------------------------|-----|
| **At Diagnosis**         |                                             |                                           |     |
| Gonadotropic deficiency  | 81/127 (64%)                                | 84/115 (73%)                              | NS  |
| Thyrotropic deficiency   | 73/127 (58%)                                | 77/116 (66%)                              | NS  |
| Corticotropic deficiency | 39/126 (31%)                                | 40/119 (34%)                              | NS  |
| Diabetes insipidus       | 2/127 (1.6%)                                | 0/119 (0%)                                | NS  |
| Number with a pituitary deficit | 95/127 (75%)                          | 102/119 (86%)                             | 0.032|
| Number of deficient axes (mean±SD) | 1.56 ± 1.17                      | 1.71 ± 1.03                               | NS  |
| **12 months post-surgery** |                                           |                                           |     |
| Gonadotropic deficiency  | 54/108 (50%)                                | 49/107 (46%)                              | NS  |
| Thyrotropic deficiency   | 44/109 (40%)                                | 50/108 (46%)                              | NS  |
| Corticotropic deficiency | 40/109 (37%)                                | 25/110 (23%)                              | 0.024|
| Diabetes insipidus       | 6/108 (6%)                                  | 10/109 (9%)                               | NS  |
| Persistent hyperprolactinaemia | 5/93 (5%)                                | 25/97 (26%)                               | 0.001|
| Number with a pituitary deficit | 67/109 (62%)                           | 66/10 (60%)                               | NS  |
| Number of deficient axes (mean±SD) | 1.33±1.29                                | 1.21±1.26                                 | NS  |
| Improvement of pituitary axes | 31/109 (28%)                           | 57/110 (52%)                               | 0.001|

**TABLE 5.** Cox univariate and multivariate analyses of factors predicting post-surgical improvement of pituitary deficiencies
| Dependent variable                        | Univariate analysis | Multivariate analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | Odds ratio 95% CI P | Odds ratio 95% CI P   |
| Older age at diagnosis (years)           | 0.978 0.967-1.008 NS| 0.978 0.967-1.008 NS  |
| Gender (female)                          | 2.128 1.162-3.896 0.014 | 1.229 0.539-2.804 NS |
| Visual disturbances at diagnosis         | 0.814 0.431-1.537 NS | NS                    |
| Hyperprolactinaemia                      | 2.231 1.225-4.066 <0.001 | 2.127 1.071-4.224 0.031 |
| Tumor height (mm)*                       | 0.957 0.922-0.994 0.023 | 0.963 0.926-1.000 0.050 |
| Tumor width (mm)*                        | 0.938 0.896-0.982 <0.001 | 0.942 0.899-0.987 0.012 |
| Invasive tumor                           | 0.692 0.379-1.265 NS | NS                    |

*Tumor height and width being correlated, these variables were introduced separately in two different multivariate analyses.

**Table 6.** Review of main studies published since 1999 on the outcome of pituitary hormonal deficits after surgery for a NFPMA
| 1st author         | Year | Ref # | Nb of patients | Type of surgery | Type of adenoma | % with pituitary deficits at diagnosis | % with pituitary deficits after surgery | Factors predicting outcome |
|--------------------|------|-------|----------------|-----------------|-----------------|---------------------------------------|----------------------------------------|---------------------------|
| Webb               | 1999 | 9     | 234            | 211 TSS/23 TC   | All types (56 NFPMA) | 50%                                   | 33%                                    | Invasion                  |
| Nomikos            | 2004 | 17    | 822            | 750 TSS/72 TC   | All types (721 NFPMA) | 85%                                   | 72%§                                   | PRL, tumor size           |
| Dekkers            | 2006 | 15    | 109            | TSS             | NFPMA            | 80%                                   | 95%                                    | None                      |
| Fatemi             | 2008 | 8     | 444            | NA              | All types (223 NFPMA) | 87%                                   | 45%                                    | Age                       |
| O’Sullivan         | 2009 | 38    | 159            | NA              | NFPMA            | GH: 90% - LH: 71%                     | GH: 91% - LH: 78%                  | NA                        |
|                    |      |       |                |                 |                 | TSH: 25% - ACTH: 50%                  | TSH: 50% - ACTH: 75%                |                           |
| Berkmann           | 2012 | 40    | 114            | TSS             | NFPMA            | 73%                                   | 63%                                    | NA                        |
| Lampropoulos       | 2013 | 36    | 184            | TSS             | All types (97 NFPMA) | 77%                                   | 52%                                    | Tumor size                |
| Jahangiri          | 2016 | 18    | 305            | TSS             | NFPMA            | 50%                                   | 34%                                    | Age, tumor size           |
| Laws               | 2016 | 39    | 80             | TSS             | All types (55 NFPMA) | 40%                                   | 44%                                    | NA                        |
| Magro              | 2016 | 41    | 300            | TSS             | NFPMA            | 60%                                   | 56%                                    | NA                        |
| Watts              | 2017 | 42    | 127            | 125 TSS/2 TC    | NFPMA            | 35% ≥2 deficits                       | 38% ≥2 deficits                   | NA                        |
| Jceng Hee Kim      | 2018 | 19    | 331            | TSS             | NFPMA            | 69%                                   | 81%                                    | None                      |
| Zhang              | 2019 | 28    | 164            | TSS             | NFPMA            | 80%                                   | 16%                                    | NA                        |
| Hwang              | 2020 | 37    | 209            | TSS             | NFPMA            | 60%                                   | 17%                                    | Age, tumor size           |
| Our series         | 2020 | 246   | TSS            | NFPMA           |                 | 80%                                   | 60%                                    | PRL, tumor size           |
| Overall results* | 3089 | NFPMA only | 2294 (74%) | 1798 (58%) |

$\%$: 69% in patients with TSS and 100% in patients with TC surgery; NFPMA: non-functioning pituitary macroadenoma; TSS: transsphenoidal surgery; TC: transcranial surgery; NA: information not available; *: the study of Watts et al was not taken into account in these calculations.